HEALTHY Study Rationale, Design and Methods: Moderating Risk of Type 2 Diabetes in Multi-Ethnic Middle School Students In this supplement the authors and study group present the rationale and design ...
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy Case reports and small prospective trials suggest ...
A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). Design and rationale of a phase 1 dose-escalation ...
PDS Biotechnology (PDSB) announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate cancer will be discussed during an oral presentation at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results